Detailed statistical analysis plan for the Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) randomised clinical trial on sildenafil versus placebo for pregnant women with severe early onset fetal growth restriction

Anouk Pels, Janus C Jakobsen, Wessel Ganzevoort, Christiana A Naaktgeboren, Wes Onland, Aleid G van Wassenaer-Leemhuis, Christian Gluud, Anouk Pels, Janus C Jakobsen, Wessel Ganzevoort, Christiana A Naaktgeboren, Wes Onland, Aleid G van Wassenaer-Leemhuis, Christian Gluud

Abstract

Objective: The objective of the Dutch Sildenafil therapy in dismal prognosis early onset fetal growth restriction (STRIDER) randomised clinical trial is to assess the beneficial and harmful effects of sildenafil versus placebo on fetal and neonatal mortality in pregnant women with severe early-onset fetal growth restriction. The objective of this detailed statistical analysis plan is to minimize the risks of selective reporting and data-driven analysis.

Setting: The setting is 10 tertiary care hospitals and one secondary care hospital in The Netherlands.

Participants: The participants will be 360 pregnant women with severe early-onset fetal growth restriction.

Interventions: The intervention is sildenafil 25 mg or placebo orally three times a day.

Primary and secondary outcome measures: The primary outcome is a composite of death or major neonatal morbidity assessed at hospital discharge. The secondary outcomes are neurodevelopmental impairment; mean scores of the Bayley III cognitive and motor assessment; the proportion of patients experiencing either preeclampsia or haemolysis, elevated liver enzymes, and low platelets syndrome; pulsatility index of uterine arteries, umbilical artery, and middle cerebral artery; birthweight; and gestational age at either delivery or intra-uterine death.

Results: A detailed statistical analysis is presented, including pre-defined exploratory outcomes and planned subgroup analyses. One interim analysis after 180 patients had completed the study was planned and a strategy to minimise the risks of type I errors due to repetitive testing is presented. During review of this manuscript the interim analysis was performed by the Data Safety Monitoring Board and early stopping of the trial was recommended. Final analyses will be conducted independently by two statistically qualified persons following the present plan.

Conclusion: This pre-specified statistical analysis plan was written and submitted without knowledge of the unblinded data and updated after stopping of the trial at interim analysis.

Trial registration: ClinicalTrials.gov, NCT02277132 . Registered on 29 September 2014. Original protocol for the study: doi: https://doi.org/10.5281/zenodo.56148.

Keywords: Fetal growth restriction; Placental insufficiency; Randomised placebo-controlled trial; Sildenafil; Statistical analysis plan.

Conflict of interest statement

Ethics approval and consent to participate

The original protocol of the Dutch STRIDER trial was approved by the local ethical committee of Academisch Medisch Centrum on 22 July 2014. Reference number 2014_131.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
CONSORT 2010 flow diagram

References

    1. Gordijn SJ, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48(3):333–339. doi: 10.1002/uog.15884.
    1. Nardozza LM, et al. Fetal growth restriction: current knowledge. Arch Gynecol Obstet. 2017;295(5):1061–1077. doi: 10.1007/s00404-017-4341-9.
    1. Severi FM, et al. Intrauterine growth retardation and fetal cardiac function. Fetal Diagn Ther. 2000;15(1):8–19. doi: 10.1159/000020969.
    1. Cauli O, et al. Treatment with sildenafil prevents impairment of learning in rats born to pre-eclamptic mothers. Neuroscience. 2010;171(2):506–512. doi: 10.1016/j.neuroscience.2010.08.065.
    1. Herraiz S, et al. Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats. BJOG. 2012;119(11):1394–1402. doi: 10.1111/j.1471-0528.2012.03430.x.
    1. Karasu E, et al. Endothelial dysfunction in the human umbilical artery due to preeclampsia can be prevented by sildenafil. Clin Exp Hypertens. 2012;34(2):79–85. doi: 10.3109/10641963.2011.628730.
    1. Maharaj CH, et al. Effects and mechanisms of action of sildenafil citrate in human chorionic arteries. Reprod Biol Endocrinol. 2009;7:34. doi: 10.1186/1477-7827-7-34.
    1. Miller SL, et al. The effects of sildenafil citrate (Viagra) on uterine blood flow and well being in the intrauterine growth-restricted fetus. Am J Obstet Gynecol. 2009;200(1):102 e1–102 e7. doi: 10.1016/j.ajog.2008.08.029.
    1. Nassar AH, et al. Effects of sildenafil in Nomega-nitro-L-arginine methyl ester-induced intrauterine growth restriction in a rat model. Am J Perinatol. 2012;29(6):429–434. doi: 10.1055/s-0032-1304823.
    1. Pellicer B, et al. Haemodynamic effects of long-term administration of sildenafil in normotensive pregnant and non-pregnant rats. BJOG. 2011;118(5):615–623. doi: 10.1111/j.1471-0528.2010.02839.x.
    1. Ramesar SV, et al. Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol. 2011;157(2):136–140. doi: 10.1016/j.ejogrb.2011.03.005.
    1. Samangaya RA, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy. 2009;28(4):369–382. doi: 10.3109/10641950802601278.
    1. Sanchez-Aparicio P, et al. Effects of sildenafil on the fetal growth of guinea pigs and their ability to survive induced intrapartum asphyxia. Am J Obstet Gynecol. 2008;198(1):127 e1–127 e6. doi: 10.1016/j.ajog.2007.06.068.
    1. Sasser JM, Baylis C. Effects of sildenafil on maternal hemodynamics and fetal growth in normal rat pregnancy. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R433–R438. doi: 10.1152/ajpregu.00198.2009.
    1. Satterfield MC, et al. Sildenafil citrate treatment enhances amino acid availability in the conceptus and fetal growth in an ovine model of intrauterine growth restriction. J Nutr. 2010;140(2):251–258. doi: 10.3945/jn.109.114678.
    1. Stanley JL, et al. Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension. 2012;59(5):1021–1028. doi: 10.1161/HYPERTENSIONAHA.111.186270.
    1. Turgut NH, et al. The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model. Eur J Pharmacol. 2008;589(1–3):180–187. doi: 10.1016/j.ejphar.2008.04.034.
    1. Villanueva-Garcia D, et al. A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. J Obstet Gynaecol. 2007;27(3):255–259. doi: 10.1080/01443610701194978.
    1. Wareing M, et al. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab. 2005;90(5):2550–5. doi: 10.1210/jc.2004-1831.
    1. Wareing M, et al. Phosphodiesterase-5 inhibitors and omental and placental small artery function in normal pregnancy and pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2006;127(1):41–49. doi: 10.1016/j.ejogrb.2004.06.014.
    1. Chen J, et al. Effect of L-arginine and sildenafil citrate on intrauterine growth restriction fetuses: a meta-analysis. BMC Pregnancy Childbirth. 2016;16:225. doi: 10.1186/s12884-016-1009-6.
    1. Dastjerdi MV, Hosseini S, Bayani L. Sildenafil citrate and uteroplacental perfusion in fetal growth restriction. J Res Med Sci. 2012;17(7):632–636.
    1. von Dadelszen P, et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG. 2011;118(5):624–628. doi: 10.1111/j.1471-0528.2010.02879.x.
    1. Trapani A, Jr, et al. Comparison between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: effects on uterine, umbilical and fetal middle cerebral artery pulsatility indices. Ultrasound Obstet Gynecol. 2016;48(1):61–65. doi: 10.1002/uog.15673.
    1. Gluud C, et al. Hepatology may have problems with putative surrogate outcome measures. J Hepatol. 2007;46(4):734–742. doi: 10.1016/j.jhep.2007.01.003.
    1. Trapani A, Jr, et al. Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: a randomized controlled trial. Obstet Gynecol. 2016;128(2):253–259. doi: 10.1097/AOG.0000000000001518.
    1. Hrobjartsson A, et al. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol. 2014;43(4):1272–1283. doi: 10.1093/ije/dyu115.
    1. Savovic J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med. 2012;157(6):429–438. doi: 10.7326/0003-4819-157-6-201209180-00537.
    1. Schulz KF, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412. doi: 10.1001/jama.1995.03520290060030.
    1. Sutton AJ, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320(7249):1574–1577. doi: 10.1136/bmj.320.7249.1574.
    1. Ganzevoort W, et al. STRIDER: sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction--a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014;3:23. doi: 10.1186/2046-4053-3-23.
    1. Andrew Sharp CC, Jackson R, Harrold J, Turner MA, Kenny LC, Baker PN, Johnstone ED, Khalil A, von Dadelszon P, Papageorghiou AT, Alfirevic Z, on behalf of the STRIDER group. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health Published Online. 2017. Lancet Child Adolesc Health. 2018;2(2):93-102.
    1. Ganzevoort W. Dutch STRIDER study protocol. 2014.
    1. Boutron I, et al. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Med. 2007;4(2):e61. doi: 10.1371/journal.pmed.0040061.
    1. Hrobjartsson A, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012;344:e1119. doi: 10.1136/bmj.e1119.
    1. Hrobjartsson A, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. CMAJ. 2013;185(4):E201–E211. doi: 10.1503/cmaj.120744.
    1. Hrobjartsson A, et al. Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. Int J Epidemiol. 2014;43(3):937–948. doi: 10.1093/ije/dyt270.
    1. Page MJ, et al. Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies. PLoS One. 2016;11(7):e0159267. doi: 10.1371/journal.pone.0159267.
    1. Savovic J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess. 2012;16(35):1–82. doi: 10.3310/hta16350.
    1. Wood L, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601–605. doi: 10.1136/.
    1. WMA Declaration of Helsinki – ethical principles for medical research involving human subjects. 2013. [Available from: /.
    1. Wet medisch-wetenschappelijk onderzoek met mensen. 2017; Available from: .
    1. Medical Research Involving Human Subjects (Medical Research (Human Subjects) Act. Available from: .
    1. De experimentenwet (7 mei 2004) en Uitvoeringsbesluit KB (koninklijk besluit) (30 juni 2004). Available from: .
    1. Guideline for Good Clinical Practice. Available from: .
    1. Kessler KM. The CONSORT statement: explanation and elaboration. Consolidated Standards of Reporting Trials. Ann Intern Med. 2002;136(12):926–927. doi: 10.7326/0003-4819-136-12-200206180-00015.
    1. L.M. Leijser, G.M., S.M. Mulder-de Tollenaer, Aanbeveling neonatale neuroimaging versie 1.5. 2015.
    1. Bancalari E, Claure N. Definitions and diagnostic criteria for bronchopulmonary dysplasia. Semin Perinatol. 2006;30(4):164–170. doi: 10.1053/j.semperi.2006.05.002.
    1. Finer NN, Bates R, Tomat P. Low flow oxygen delivery via nasal cannula to neonates. Pediatr Pulmonol. 1996;21(1):48–51. doi: 10.1002/(SICI)1099-0496(199601)21:1<48::AID-PPUL8>;2-M.
    1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723–1729. doi: 10.1164/ajrccm.163.7.2011060.
    1. Walsh MC, et al. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003;23(6):451–6. doi: 10.1038/sj.jp.7210963.
    1. Walsh MC, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. 2004;114(5):1305–1311. doi: 10.1542/peds.2004-0204.
    1. Kindergeneeskunde, N.V.v . Richtlijn Bronchopulmonaire dysplasie. 2013.
    1. (NOG), N.O.G . Richtlijn Prematuren Retinopathie. 2012.
    1. Bell MJ, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187(1):1–7. doi: 10.1097/00000658-197801000-00001.
    1. Bayley N. Bayley Scales of Infant and Toddler Development—Third Edition: Administration manual. 2006.
    1. (NVOG), N.V.v.O.e.G. Hypertensieve aandoeningen in de zwangerschap. 2011.
    1. Saphier CJ, Repke JT. Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a review of diagnosis and management. Semin Perinatol. 1998;22(2):118–133. doi: 10.1016/S0146-0005(98)80044-X.
    1. Onderzoeksprotocol The Dutch STRIDER 10.5281/zenodo.56148.
    1. Lees CC, et al. Two-year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015;385(9983):2162–2172. doi: 10.1016/S0140-6736(14)62049-3.
    1. Lees C, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE) Ultrasound Obstet Gynecol. 2013;42(4):400–408. doi: 10.1002/uog.13190.
    1. Dutch STRIDER: Data Monitoring Committee Charter 10.5281/zenodo.56147.
    1. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549–556. doi: 10.2307/2530245.
    1. Ashby D, Machin D. Stopping rules, interim analyses and data monitoring committees. Br J Cancer. 1993;68(6):1047–1050. doi: 10.1038/bjc.1993.481.
    1. Jakobsen JC, et al. The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med Res Methodol. 2014;14:34. doi: 10.1186/1471-2288-14-34.
    1. Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17(1):39. doi: 10.1186/s12874-017-0315-7.
    1. Jakobsen, J.C., Systematic reviews of randomised clinical trials examining the effects of psychotherapeutic interventions versus ‘no intervention’ for major depressive disorder and a randomised trial examining the effects of ‘third wave’ cognitive therapy versus mentalization-based treatment for major depressive dis-order. Ph.D. Thesis, 2013: p. 1–62.
    1. Goodman SN. Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials. 2005;2(4):282–290. doi: 10.1191/1740774505cn098oa.
    1. McNutt LA, et al. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157(10):940–943. doi: 10.1093/aje/kwg074.
    1. Jakobsen JC, et al. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162. doi: 10.1186/s12874-017-0442-1.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa